-
Notice of the General Office of the Ministry of Finance of the Office of the National Medical Insurance Administration on the implementation of the pilot work for direct settlement of outpatient chronic diseases related treatment costs across provinces
Time of Update: 2021-09-19
In pilot areas, among the designated medical institutions that have opened direct settlement of general outpatient medical expenses across provinces, priority is given to selecting high-level diagnosis and treatment, standardized management, and completing medical insurance disease diagnosis, medical insurance drugs, medical service items, medical consumables, outpatient chronic diseases, etc.
-
The "2021 Internet Hospital Report" was released, with data analysis of 1,140 and 109 full-dimensional surveys, revealing these core trends
Time of Update: 2021-09-19
Changes in the scale of online medical netizens, data source: China Internet Network Information Center, Eggshell Research Institute In the "Internet Diagnosis and Treatment Platform's Re-examination Experience Survey of Tuberculosis Patients" conducted by the Beijing Chest Hospital affiliated to Capital Medical University, I chose to participate in online consultations from February to June 2020, and complete the entire process of Internet diagnosis and treatment and drug delivery.
-
BeiGene tislelizumab for the treatment of esophageal squamous cell carcinoma has been accepted by the FDA, and 4 PD-1 models have been listed in the United States in China
Time of Update: 2021-09-19
It is reported that BeiGene's listing application is based on the results of a randomized, open, multi-center global phase 3 clinical trial RATIONALE 302 (NCT03430843), which aims to evaluate the comparative study of tislelizumab injection The effectiveness and safety of the chemotherapy selected by the patient for the second-line treatment of patients with advanced or metastatic ESCC .
-
Problems to be solved in the commercial production of biopharmaceuticals
Time of Update: 2021-09-19
China's biopharmaceutical industry is booming and its influence is reaching the world. In the past ten years, the global biopharmaceutical market competitiveness has increased significantly. China
-
Junshi Biological released the first-line Phase III study data of Teriprizumab in the World Lung Cancer Conference (WCLC) for the first-line treatment of non-small cell lung cancer
Time of Update: 2021-09-19
08) for the first phase III key registration of teriprizumab combined with chemotherapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Interim analysis results of the clinical study (CHOICE-01 study) .
-
The wAMD treatment is expected to require only one injection!
Time of Update: 2021-09-19
On September 13, AbbVie and Regenxbio announced that they have reached the development and commercialization of the gene therapy RGX-314 for the treatment of age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic eye diseases Chemical cooperation agreement .
-
China's rare disease definition research report released: rare diseases with fewer than 140,000 patients
Time of Update: 2021-09-19
In addition, after the redefinition of rare diseases, orphan drugs also need to have a standard suitable for national conditions, so that China's rare disease prevention and control can be standardized and institutionalized .
-
Hebo Pharma's new-generation anti-CTLA-4 antibody HBM4003 was approved for two clinical trials in China
Time of Update: 2021-09-19
Hebo Pharmaceutical recently announced that the National Medical Products Administration (NMPA) of China approved its new generation of HBM4003 anti-CTLA-4 fully human monoclonal heavy chain antibody and PD-1 antibody for the treatment of advanced hepatocellular carcinoma (HCC) and other solid tumors Clinical trial application for patients, and clinical trial application for HBM4003 and PD-1 antibody combined treatment of advanced neuroendocrine tumor/carcinoma (NET/NEC) and other solid tumor patients .
-
Cinda’s first SIRPα antibody, will CD47/SIRPα be the next piece of the Red Sea?
Time of Update: 2021-09-19
In addition to IBI397, Cinda also has two drugs under development that target the CD47/SIRPα signaling pathway .
(Targeting the mechanism of CD47-SIRPα pathway in tumors Source: [3]) Cinda BioCinda Bio Founded in 2011, Cinda Bio is committed to the development, production and sales of innovative drugs for the treatment of major diseases such as tumors .
-
Chia Tai Tianqing, Hausen, Hengrui...78 new drugs were approved for clinical use, Qilu biologics broke out, and influenza 1 new drugs struck
Time of Update: 2021-09-19
10) Approved domestic/imported new drug listing application Disulumab is a "first-in-class" anti-RANKL monoclonal antibody developed by Amgen, with global sales of approximately US$5 billion in 2020 .
-
The disease control rate reaches 100%!
Time of Update: 2021-09-19
com/s/uKRytToz1p-0n4EZbFi2jw[1] The interim results of the phase I clinical trial study of EpCAM/CD3 dual antibody for the treatment of malignant ascites at the ESMO annual meeting in 2021 are online.
-
Speed reading agency Rongchang Biological Vidicuzumab's new indications are included in the priority review and multiple provinces determine the implementation time of the fifth batch of centralized procurement
Time of Update: 2021-09-19
2 monoclonal antibody clinical application On the 10th, Junshi Bio announced that the submitted clinical trial application for JS012 injection has been accepted by NMPA for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer .
-
PD-1 goes to sea!
Time of Update: 2021-09-19
The listing application is a joint application by Baekje and Novartis, based on the results of a randomized, open, multi-center global phase 3 clinical trial RATIONALE 302 (NCT03430843) , which aims to evaluate the choice of researchers for the comparison of Bazeran® The effectiveness and safety of advanced chemotherapy for second-line treatment of patients with advanced or metastatic ESCC .
-
Bojian’s high-priced SMA drugs are on the hot search again, where is the “difficult” drug for rare diseases?
Time of Update: 2021-09-19
However, the Medical Insurance Bureau also admitted that some particularly expensive drugs for special rare diseases cannot be included in the basic medical insurance payment due to reasons such as far exceeding the fund and the affordability of patients .
-
Registration method for the Shenzhen Stock Exchange's GEM Special Symposium
Time of Update: 2021-09-19
In order to help various innovative entities in the pharmaceutical industry better understand the ChiNext listing policy, build a bridge between the pharmaceutical industry and the capital market, pr
-
The formula pellets rose fiercely, and the two leading companies broke 7 billion in half a year!
Time of Update: 2021-09-19
It is mentioned in the semi-annual report that with the company's increased recognition of the quality controllability of traditional Chinese medicine formula granules and the operation mode of dispensing machines, the business of this sector has developed rapidly and the gross profit margin has increased steadily .
-
BeiGene: Forward-looking layout, steady and steady winning model
Time of Update: 2021-09-19
As a guide, we have promoted the research and development of innovative drugs in accordance with international standards, and won the favor of the world's top investment and multinational pharmaceutical companies, embarking on a unique development path .
-
42 new drugs have been approved for clinical use, and dual-antibody drugs have exploded!
Time of Update: 2021-09-19
This time, the product was approved for clinical use in China and is intended to be developed for advanced solid tumors .
This time, HMPL-453 was approved for clinical use in China, and the proposed development indications are: combined chemotherapy or anti-PD-1 monoclonal antibody for patients with advanced solid tumors .
-
Analyze the research and development efficiency of the world's leading pharmaceutical companies in the past 20 years, and reveal the survival methods of pharmaceutical companies of different sizes
Time of Update: 2021-09-19
The latest issue of Drug Discovery Today published a paper on R&D efficiency of leading pharmaceutical companies — a 20-year analysis, which analyzed the R&D data of 14 global drug R&D le
-
Insulin special collection varieties + company list announcement, involving 81 products
Time of Update: 2021-09-19
On September 10, Shanghai Sunshine Pharmaceutical Purchasing Network released the sixth batch of second- and third-generation insulin-related companies and products for centralized drug procurement (insulin special) organized by the state.
The following is a list of specific products and companies:
